Itulazax

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as an unknown strength/unknown form for sublingual use. It is employed to treat birch pollen allergy, allergic rhinitis caused by Betula verrucosa, and seasonal allergic rhinoconjunctivitis by promoting immunological tolerance in patients.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution across multiple regulatory jurisdictions.

Itulazax is used in allergen immunotherapy for birch pollen–related conditions.

Birch pollen allergy: reduces nasal and ocular symptoms by inducing immune tolerance. Allergic rhinitis due to Betula verrucosa: improves nasal congestion and sneezing through sublingual exposure. Seasonal allergic rhinoconjunctivitis: lessens conjunctival irritation and rhinorrhea by shifting the immune response.

Side effects are generally mild and related to local exposure, but rare systemic reactions can occur.

Common Side Effects: - Oral itching or mild irritation - Throat discomfort - Transient swelling of the lips or tongue - Mild gastrointestinal upset - Headache - Localized rash

Serious or Rare Side Effects: - Anaphylaxis - Severe oral or facial edema - Systemic allergic reaction - Asthma exacerbation - Urticaria - Severe dizziness or loss of consciousness

Before initiating therapy, consider patient‑specific factors and follow safe handling practices.

Medical evaluation: assess severity of birch pollen allergy before initiating therapy. Age considerations: use only in patients for whom sublingual immunotherapy is indicated. Concomitant medications: review antihistamines or immunosuppressants. Pregnancy and lactation: safety not established; weigh risks and benefits. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Potential drug interactions should be reviewed to minimize risk.

Major Interactions (Avoid): - Beta‑blockers: may mask anaphylaxis symptoms. - ACE inhibitors: increase risk of angioedema. - Immunosuppressants: may reduce efficacy of immunotherapy.

Moderate Interactions (Monitor Closely): - Antihistamines: may diminish local side effects but not overall efficacy. - Corticosteroids: may affect immune response if used systemically. - Vaccines: schedule immunotherapy away from live vaccines.